Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALLO 
Allogene Therapeutics Inc (ALLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ALLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $8.15
Year Target Price $8.15
| 8 | Strong Buy |
| 4 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.25% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 258.10M USD | Price to earnings Ratio - | 1Y Target Price 8.15 |
Price to earnings Ratio - | 1Y Target Price 8.15 | ||
Volume (30-day avg) 14 | Beta 0.31 | 52 Weeks Range 0.86 - 3.78 | Updated Date 06/29/2025 |
52 Weeks Range 0.86 - 3.78 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.92% | Return on Equity (TTM) -59.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 59351354 | Price to Sales(TTM) 11631.14 |
Enterprise Value 59351354 | Price to Sales(TTM) 11631.14 | ||
Enterprise Value to Revenue 3859.62 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 218731008 | Shares Floating 157188709 |
Shares Outstanding 218731008 | Shares Floating 157188709 | ||
Percent Insiders 17.74 | Percent Institutions 80.54 |
Analyst Ratings
Rating 4 | Target Price 8.15 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Allogene Therapeutics Inc
Company Overview
History and Background
Allogene Therapeutics, Inc. was founded in 2018 after acquiring Pfizer's allogeneic CAR T program. The company focuses on developing allogeneic CAR T (AlloCAR Tu2122) therapies for cancer.
Core Business Areas
- AlloCAR Tu2122 Therapy Development: Allogene's primary focus is the research and development of allogeneic CAR T cell therapies for various hematologic malignancies and solid tumors. This involves cell engineering, clinical trials, and manufacturing.
Leadership and Structure
David Chang is the President and CEO. The company has a structured management team overseeing research, development, clinical operations, and manufacturing.
Top Products and Market Share
Key Offerings
- AlloCAR Tu2122 Programs: Allogene's lead product candidates are AlloCAR T cell therapies in various stages of clinical development. The primary focus is on hematological malignancies. There are currently no marketed products. Competitors include companies developing autologous CAR T therapies such as Gilead (Kite Pharma) and Novartis.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in gene editing and immunotherapy. The allogeneic CAR T cell therapy segment is particularly promising due to its potential for off-the-shelf availability and scalability.
Positioning
Allogene is positioned as a leader in the allogeneic CAR T cell therapy space. The advantage of this approach is the 'off-the-shelf' availability which is better than autologous therapies which can be time consuming and costly.
Total Addressable Market (TAM)
The TAM for cell therapy in oncology is estimated to reach billions of dollars. Allogene is positioned to capture a portion of this market through successful development and commercialization of its AlloCAR Tu2122 programs.
Upturn SWOT Analysis
Strengths
- Pioneering allogeneic CAR T technology
- Experienced management team
- Strong intellectual property portfolio
- Potential for off-the-shelf CAR T therapy
Weaknesses
- Clinical development risks
- Manufacturing complexities
- High cash burn rate
- Regulatory hurdles
Opportunities
- Expanding AlloCAR T applications to solid tumors
- Strategic partnerships with pharmaceutical companies
- Advancements in cell engineering technologies
- Addressing unmet needs in hematologic malignancies
Threats
- Competition from autologous CAR T therapies
- Adverse clinical trial outcomes
- Regulatory setbacks
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GILD
- NVS
- CRSP
Competitive Landscape
Allogene faces competition from companies developing autologous CAR T therapies and other novel cancer immunotherapies. Allogene's advantage lies in its allogeneic approach, but it must overcome clinical and regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by the advancement of clinical programs and the expansion of the company's pipeline.
Future Projections: Future growth is contingent on positive clinical trial results, regulatory approvals, and successful commercialization of AlloCAR Tu2122 therapies. Analyst estimates vary widely depending on clinical outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials, expanding manufacturing capabilities, and exploring new AlloCAR Tu2122 targets.
Summary
Allogene Therapeutics is a pioneering company in the allogeneic CAR T cell therapy field. Its potential for off-the-shelf therapies provides a strong advantage over the autologous approach. However, the company faces high clinical development risks, regulatory challenges, and intense competition. Success hinges on positive clinical trial outcomes and effective commercialization strategies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company Website
- Analyst Reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allogene Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Dr. David D. Chang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 226 | Website https://allogene.com |
Full time employees 226 | Website https://allogene.com | ||
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.